DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

ASCO 2018 Highlights: Key Oncology Landscape Updates and Implications for the Life Sciences Industry

DRG Oncology experts joined nearly 40,000 oncology professionals at the 2018 Annual Meeting to get a download of the latest data and innovations in the space.

Out of the many sessions and abstracts we reviewed, we compiled a brief of key meeting highlights and industry implications for our oncology clients as they plan for the future:

  • Merck set to consolidate its dominant position in first-line metastatic NSCLC
  • ASCO 2018 highlights difficulties developing combinations with immune checkpoint inhibitors
  • Innovative therapies for bladder cancer outside of the immune space
  • Last, but not least: KEYNOTE-045 in bladder cancer
  • Post ASCO Update: Avastin’s FDA approval in first-line ovarian cancer – what are the market implications?